Connext

The firm's core strategy centers on its microorganism-based recombinant protein production technology. This approach is positioned as a more efficient and cost-effective alternative to traditional animal-cell-based production due to faster growth rates and lower cultivation expenses. Connext operates as a 'Specialty Pharma' company, targeting conditions where manufacturing technology barriers are high. The business model involves generating revenue through technology licensing fees and product sales, often in partnership with overseas pharmaceutical companies. The company also plans to establish its own GMP-certified manufacturing facilities to sell drug products directly.

Connext's development pipeline includes two main candidates. The first is CNT201, a 'Best-in-Class' recombinant collagenase being developed as a non-surgical treatment for Dupuytren's contracture. Unlike existing treatments derived from pathogenic microorganisms, CNT201 is a synthetic protein-based therapeutic, which enhances production consistency and safety. The company has completed the dose-escalation part of a Phase 1/2 clinical trial for CNT201 and plans to initiate Phase 2 trials in late 2025, with a goal of entering Phase 3 in 2027. Connext is also exploring the expansion of CNT201's applications to include Peyronie's disease and cellulite treatment. The second key product is CNT101, a 'first-in-class' recombinant TLR5 agonist designed to prevent side effects from radiation and chemotherapy, with a focus on treating conditions like acute graft-versus-host disease.

Headquartered in Daegu, South Korea, Connext has secured multiple rounds of funding and received accolades, including a commendation from the Minister of Health and Welfare in November 2023. The company is preparing for an Initial Public Offering (IPO) on the KOSDAQ market, having signed an underwriting agreement with Korea Investment & Securities.